Leah J Witt Carley Demchuk James J Curran Mary E Strek
10.1016/j.pupt.2015.12.004
Pulm Pharmacol Ther
2016 Feb;36:46-52.
autoimmune disease idiopathic inflammatory myopathies immunosuppression interstitial lung disease
author_manuscript
https://pubmed.ncbi.nlm.nih.gov/26762710/
Connective Tissue Diseases / drug therapy Immunosuppressive Agents / therapeutic use Lung Diseases, Interstitial / drug therapy Tacrolimus / therapeutic use
Connective Tissue Diseases / drug therapy Immunosuppressive Agents / therapeutic use Lung Diseases, Interstitial / drug therapy Tacrolimus / therapeutic use Case Reports Research Support, N.I.H., Extramural Adrenal Cortex Hormones / administration & dosage Adrenal Cortex Hormones / therapeutic use Adult Aged Anti-Inflammatory Agents / administration & dosage Anti-Inflammatory Agents / therapeutic use Connective Tissue Diseases / diagnostic imaging Connective Tissue Diseases / physiopathology Dermatomyositis / drug therapy Drug Therapy, Combination Female Humans Immunosuppressive Agents / adverse effects Lung Diseases, Interstitial / diagnostic imaging Lung Diseases, Interstitial / physiopathology Male Middle Aged Monitoring, Physiologic Radiography Respiratory Function Tests Retrospective Studies Tacrolimus / adverse effects Total Lung Capacity Treatment Outcome Vital Capacity Adrenal Cortex Hormones Anti-Inflammatory Agents Immunosuppressive Agents Tacrolimus
PMC4760686
26762710
Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease
2016